Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 08-Jul-24 4:02 PM View:  | Huang Jane President, CMO | Prelude Therapeutics Inc (PRLD) | 04-Jul-24 | Option Exercise | 9,375 | -- | -- | 18% 51.29K to 60.66K | |
| 08-Jul-24 4:02 PM View: | Huang Jane President, CMO | Prelude Therapeutics Inc (PRLD) | 04-Jul-24 | Payment of Exercise | 3,347 | $3.60 | $12,049.20 | (6%) 60.66K to 57.31K | |
| 08-Apr-24 4:11 PM View: | Huang Jane President, CMO | Prelude Therapeutics Inc (PRLD) | 04-Apr-24 | Option Exercise | 9,375 | -- | -- | 21% 45.26K to 54.63K | |
| 08-Apr-24 4:11 PM View: | Huang Jane President, CMO | Prelude Therapeutics Inc (PRLD) | 04-Apr-24 | Payment of Exercise | 3,347 | $4.74 | $15,864.80 | (6%) 54.63K to 51.29K | |
| 08-Jan-24 5:00 PM View: | Huang Jane President, CMO | Prelude Therapeutics Inc (PRLD) | 04-Jan-24 | Option Exercise | 9,375 | -- | -- | 24% 39.73K to 49.1K | |
| 08-Jan-24 5:00 PM View: | Huang Jane President, CMO | Prelude Therapeutics Inc (PRLD) | 04-Jan-24 | Payment of Exercise | 3,844 | $3.77 | $14,491.90 | (8%) 49.1K to 45.26K | |
| 06-Oct-23 9:07 AM View: | Huang Jane President, CMO | Prelude Therapeutics Inc (PRLD) | 04-Oct-23 | Option Exercise | 9,375 | -- | -- | 31% 30.35K to 39.73K | |
| 06-Jul-23 4:35 PM View: | Huang Jane President, CMO | Prelude Therapeutics Inc (PRLD) | 04-Jul-23 | Option Exercise | 9,375 | -- | -- | 39% 24.22K to 33.59K | |
| 06-Jul-23 4:35 PM View: | Huang Jane President, CMO | Prelude Therapeutics Inc (PRLD) | 04-Jul-23 | Payment of Exercise | 3,242 | $4.65 | $15,075.30 | (10%) 33.59K to 30.35K | |
| 26-May-23 4:20 PM View: | Vaddi Krishna CEO Director | Prelude Therapeutics Inc (PRLD) | 25-May-23 | Purchase | 900 | $5.31 | $4,779.00 | < 1% 2.71M to 2.72M | |
| 26-May-23 4:20 PM View: | Vaddi Krishna CEO Director | Prelude Therapeutics Inc (PRLD) | 24-May-23 | Private Purchase | 1,000 | $5.01 | $5,011.40 | < 1% 2.71M to 2.71M | |
| 25-May-23 4:07 PM View: | Lim Bryant David Chief Legal Officer, Corp Sec. | Prelude Therapeutics Inc (PRLD) | 24-May-23 | Private Purchase | 2,400 | $5.39 | $12,936.00 | 100% 0 to 2.4K | |
| 25-May-23 4:05 PM View: | Chardonnet Laurent Chief Financial Officer | Prelude Therapeutics Inc (PRLD) | 23-May-23 | Private Purchase | 5,000 | $5.50 | $27,500.00 | 13% 37.16K to 42.16K | |
| 25-May-23 4:03 PM View: | Vaddi Krishna CEO Director | Prelude Therapeutics Inc (PRLD) | 23-May-23 | Private Purchase | 11,856 | $5.63 | $66,749.30 | < 1% 2.7M to 2.71M | |
| 24-May-23 5:07 PM View: | Bonita David P Director 10% Owner | Prelude Therapeutics Inc (PRLD) | 22-May-23 | Private Purchase | 869,565 | $5.75 | $5,000,000.00 | 9% 9.78M to 10.65M | |
| 24-May-23 5:09 PM View: | Orbimed Advisors LLC Director 10% Owner | Prelude Therapeutics Inc (PRLD) | 22-May-23 | Private Purchase Duplicate | 869,565 | $5.75 | $5,000,000.00 | 9% 9.78M to 10.65M | |
| 06-Apr-23 6:19 PM View: | Huang Jane President, CMO | Prelude Therapeutics Inc (PRLD) | 06-Apr-23 | Option Sale | 13,280 | $6.12 | $81,273.60 | (35%) 37.5K to 24.22K | |
| 06-Apr-23 6:19 PM View: | Huang Jane President, CMO | Prelude Therapeutics Inc (PRLD) | 04-Apr-23 | Option Exercise | 37,500 | -- | -- | 100% 0 to 37.5K | |
| 21-Dec-22 4:08 PM View: | Vaddi Krishna CEO Director | Prelude Therapeutics Inc (PRLD) | 20-Dec-22 | Private Purchase | 19,188 | $5.13 | $98,446.00 | < 1% 2.68M to 2.7M | |
| 12-Dec-22 9:13 AM View: | Chardonnet Laurent Chief Financial Officer | Prelude Therapeutics Inc (PRLD) | 08-Dec-22 | Private Purchase | 10,000 | $4.76 | $47,600.00 | 39% 25.87K to 35.87K | |
| 01-Jun-22 4:31 PM View: | Chardonnet Laurent Chief Financial Officer | Prelude Therapeutics Inc (PRLD) | 01-Jun-22 | Private Purchase | 10,000 | $4.23 | $42,300.00 | 69% 14.5K to 24.5K | |
| 04-Apr-22 5:08 PM View: | Combs Andrew EVP, Head of Chemistry | Prelude Therapeutics Inc (PRLD) | 31-Mar-22 | Option Exercise | 36,062 | $1.89 | $68,157.20 | 13% 268.38K to 304.44K | |
| 22-Mar-22 6:01 PM View: | Chardonnet Laurent Chief Financial Officer | Prelude Therapeutics Inc (PRLD) | 21-Mar-22 | Grant | 6,500 | $7.51 | $48,815.00 | 81% 8.0K to 14.5K | |
| 17-Dec-21 5:20 PM View: | Morosini Deborah EVP, Chief of Clinical Affairs | Prelude Therapeutics Inc (PRLD) | 15-Dec-21 | Option Exercise | 28,751 | $11.70 | $336,395.00 | 6475% 0.44K to 29.2K | 17% |
| 17-Dec-21 5:20 PM View: | Morosini Deborah EVP, Chief of Clinical Affairs | Prelude Therapeutics Inc (PRLD) | 15-Dec-21 | Market Option Sale (Planned) | 28,751 | $13.00 | $373,763.00 | (98%) 29.2K to 0.44K | (5%) |
| 15-Dec-21 5:21 PM View: | Combs Andrew EVP, Head of Chemistry | Prelude Therapeutics Inc (PRLD) | 14-Dec-21 | Market Purchase | 4,000 | $11.60 | $46,400.00 | 2% 264.38K to 268.38K | 3% |
| 14-Dec-21 5:36 PM View: | Vaddi Krishna President, CEO Director | Prelude Therapeutics Inc (PRLD) | 13-Dec-21 | Grant | 8,000 | $12.13 | $97,035.20 | < 1% 2.57M to 2.58M | (< 1%) |
| 15-Dec-21 5:21 PM View: | Combs Andrew EVP, Head of Chemistry | Prelude Therapeutics Inc (PRLD) | 13-Dec-21 | Market Purchase | 4,000 | $12.12 | $48,480.00 | 2% 260.38K to 264.38K | (2%) |
| 14-Dec-21 5:37 PM View: | Chardonnet Laurent Chief Financial Officer | Prelude Therapeutics Inc (PRLD) | 13-Dec-21 | Grant | 5,000 | $12.28 | $61,400.00 | 167% 3.0K to 8.0K | (1%) |
| 18-Nov-21 6:42 PM View: | Morosini Deborah EVP, Chief of Clinical Affairs | Prelude Therapeutics Inc (PRLD) | 16-Nov-21 | Option Exercise | 28,751 | $12.85 | $369,450.00 | 6475% 0.44K to 29.2K | |
| 18-Nov-21 6:42 PM View: | Morosini Deborah EVP, Chief of Clinical Affairs | Prelude Therapeutics Inc (PRLD) | 16-Nov-21 | Market Option Sale (Planned) | 28,751 | $15.88 | $456,532.00 | (98%) 29.2K to 0.44K | |
| 06-Oct-21 6:02 PM View: | Mauro David J Chief Medical Officer | Prelude Therapeutics Inc (PRLD) | 05-Oct-21 | Market Option Sale (Planned) | 15,000 | $30.96 | $464,350.00 | (100%) 15.0K to 0 | |
| 06-Oct-21 6:02 PM View: | Mauro David J Chief Medical Officer | Prelude Therapeutics Inc (PRLD) | 05-Oct-21 | Option Exercise | 15,000 | $1.89 | $28,350.00 | 100% 0 to 15.0K | |
| 09-Sep-21 10:00 PM View: | Mauro David J Chief Medical Officer | Prelude Therapeutics Inc (PRLD) | 07-Sep-21 | Option Exercise | 15,000 | $1.89 | $28,350.00 | 100% 0 to 15.0K | |
| 09-Sep-21 10:00 PM View: | Mauro David J Chief Medical Officer | Prelude Therapeutics Inc (PRLD) | 07-Sep-21 | Market Option Sale (Planned) | 15,000 | $36.69 | $550,283.00 | (100%) 15.0K to 0 | |
| 07-Sep-21 7:17 PM View: | Pierce Christopher EVP and Chief of Business Oper | Prelude Therapeutics Inc (PRLD) | 02-Sep-21 | Market Option Sale (Planned) | 17,000 | $41.68 | $708,493.00 | (82%) 20.75K to 3.75K | |
| 07-Sep-21 7:17 PM View: | Pierce Christopher EVP and Chief of Business Oper | Prelude Therapeutics Inc (PRLD) | 02-Sep-21 | Option Exercise | 17,000 | $12.85 | $218,450.00 | 453% 3.75K to 20.75K | |
| 30-Aug-21 5:16 PM View: | Scherle Peggy Chief Scientific Officer | Prelude Therapeutics Inc (PRLD) | 27-Aug-21 | Market Option Sale (Planned) | 6,014 | $35.91 | $215,967.00 | (3%) 178.93K to 172.92K | |
| 30-Aug-21 5:16 PM View: | Scherle Peggy Chief Scientific Officer | Prelude Therapeutics Inc (PRLD) | 27-Aug-21 | Option Exercise | 6,014 | $1.43 | $8,600.02 | 3% 172.92K to 178.93K | |
| 30-Aug-21 5:16 PM View: | Scherle Peggy Chief Scientific Officer | Prelude Therapeutics Inc (PRLD) | 26-Aug-21 | Option Exercise | 1,700 | $1.43 | $2,431.00 | < 1% 172.92K to 174.62K | |
| 30-Aug-21 5:16 PM View: | Scherle Peggy Chief Scientific Officer | Prelude Therapeutics Inc (PRLD) | 26-Aug-21 | Market Option Sale (Planned) | 1,700 | $35.19 | $59,819.40 | (< 1%) 174.62K to 172.92K | |
| 27-Aug-21 8:02 PM View: | Piper Brian Chief Financial Officer | Prelude Therapeutics Inc (PRLD) | 25-Aug-21 | Market Option Sale (Planned) | 8,333 | $33.34 | $277,827.00 | (100%) 8.33K to 0 | |
| 27-Aug-21 8:02 PM View: | Piper Brian Chief Financial Officer | Prelude Therapeutics Inc (PRLD) | 25-Aug-21 | Option Exercise | 8,333 | $1.89 | $15,749.40 | 100% 0 to 8.33K | |
| 17-Aug-21 4:44 PM View: | Scherle Peggy Chief Scientific Officer | Prelude Therapeutics Inc (PRLD) | 13-Aug-21 | Option Exercise | 2,286 | $1.54 | $3,525.66 | 1% 172.92K to 175.21K | |
| 17-Aug-21 4:44 PM View: | Scherle Peggy Chief Scientific Officer | Prelude Therapeutics Inc (PRLD) | 13-Aug-21 | Market Option Sale (Planned) | 2,286 | $35.07 | $80,161.30 | (1%) 175.21K to 172.92K | |
| 09-Aug-21 4:26 PM View: | Mauro David J Chief Medical Officer | Prelude Therapeutics Inc (PRLD) | 05-Aug-21 | Option Exercise | 15,000 | $1.89 | $28,350.00 | 100% 0 to 15.0K | |
| 09-Aug-21 4:26 PM View: | Mauro David J Chief Medical Officer | Prelude Therapeutics Inc (PRLD) | 05-Aug-21 | Market Option Sale (Planned) | 15,000 | $31.09 | $466,394.00 | (100%) 15.0K to 0 | |
| 29-Jul-21 7:27 PM View: | Scherle Peggy Chief Scientific Officer | Prelude Therapeutics Inc (PRLD) | 27-Jul-21 | Market Option Sale (Planned) | 20,000 | $35.47 | $709,380.00 | (10%) 192.92K to 172.92K | |
| 29-Jul-21 7:27 PM View: | Scherle Peggy Chief Scientific Officer | Prelude Therapeutics Inc (PRLD) | 27-Jul-21 | Option Exercise | 20,000 | $1.43 | $28,600.00 | 12% 172.92K to 192.92K | |
| 08-Jul-21 5:41 PM View: | Mauro David J Chief Medical Officer | Prelude Therapeutics Inc (PRLD) | 06-Jul-21 | Market Option Sale (Planned) | 15,000 | $27.47 | $412,107.00 | (100%) 15.0K to 0 |
